BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 21447872)

  • 1. HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection.
    Hsu SJ; Hsu CS; Liu CH; Liu CJ; Chen CL; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(2):227-35. PubMed ID: 21447872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
    Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
    Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
    Ogura S; Akuta N; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Kobayashi M; Suzuki F; Suzuki Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2009; 52(4):179-88. PubMed ID: 19546575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic hepatitis C].
    Grammatikos G; Sarrazin C
    Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Pellicano R; Puglisi G; Ciancio A; Balzola F; Saracco G; Ciccone G; Baldi I; Abate ML; Smedile A; Rizzetto M
    J Med Virol; 2008 Apr; 80(4):628-31. PubMed ID: 18297716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.
    Akuta N; Suzuki F; Kobayashi M; Sezaki H; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Clin Microbiol; 2015 Sep; 53(9):3039-41. PubMed ID: 26135874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis.
    el-Khattib AA; Abdelhakam SM; Ghoraba DM; Ibrahim WA; Sayed MM
    Eur J Intern Med; 2012 Jan; 23(1):e34-5. PubMed ID: 22153547
    [No Abstract]   [Full Text] [Related]  

  • 20. Amino acid substitutions in the core region associate with insulin resistance in chronic hepatitis C.
    Hung CH; Hu TH; Lee CM; Huang CM; Chen CH; Wang JH; Lu SN
    Intervirology; 2013; 56(3):166-71. PubMed ID: 23406967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.